Medivation shares rise in pre-market on positive results in drug trial

Medivation Inc. (Nasdaq:MDVN) is up more than 3% in pre-market trading today after the biopharmaceutical company announced after the close on Monday that Dimebon, an investigational drug, had improved brain function in patients with mild forms of Huntington’s disease during Phase 2 trials. Huntington’s affects brain cells and leads to uncontrollable movements and loss of cognitive function. The drug is now being tested on patients with Alzheimer’s, the San Francisco-based company said.

Ahead of the opening bell today, Medivation shares are at $12.50, up $0.44 or 3.65%, from Monday’s close.

For detailed price information and recent news stories on Medivation Inc., click MDVN.

---